Guardant Health, Inc. GH
Set alert
At close · Oct 30
After hours · Oct 30, 4:03 PM ET
- YTD
- +75.05%
- 1 year
- +93.49%
- Open
- 182.48
- Prev close
- 185.31
- Mkt cap
- 23.99B
- Vol
- 1.50M
- Avg vol
- 1.94M
- EPS
- -3.50
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 175.44
- High
- 185.65
- Forward P/E
- -471.56
- Beta
- 1.58
- Short ratio
- 6.12
- Inst. own
- 100.98%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 169.49
- 200-d avg
- 130.15
- 1y target
- 202.24
5D chart
Events in this range
- Oct 27, 2026Rating: BTIG · Buy → Buy
Signals (130)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:20 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:05 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 3:05 PM | 1 day ago |
| RSI: Oversold | Oct 30, 2:40 PM | 1 day ago |
| RSI: Oversold | Oct 30, 2:30 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 2:25 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:15 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:05 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:00 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:45 PM | 1 day ago |
| SMA: Bearish | Oct 30, 1:30 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:15 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:20 PM | 2 days ago |
| RSI: Oversold | Oct 30, 12:00 PM | 2 days ago |
| RSI: Oversold | Oct 30, 11:40 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:25 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:00 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:50 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:20 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:20 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 3:05 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:55 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 2:35 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:15 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 11:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:35 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:35 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:45 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| RSI: Oversold | Oct 28, 3:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:55 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:20 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:15 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:10 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:55 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:20 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:50 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 5 days ago |
| RSI: Oversold | Oct 26, 3:20 PM | 5 days ago |
| RSI: Oversold | Oct 26, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:35 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:35 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:20 AM | 6 days ago |
News
3 days ago zacks.com
Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 days ago businesswire.com
Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, applauded the enactment of a new law (HB 1123) in Pennsylvania aligning insurance…
4 days ago seekingalpha.com
Allspring Emerging Growth Fund: Q3 2026 Top Contributors And Detractors
After delivering results well above expectations, TWST management significantly raised its outlook and projected triple-digit growth in orders. During the quarter, LIFE shares performed well…
-
5 days ago benzinga.com
BTIG Maintains Buy on Guardant Health, Raises Price Target to $210
BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $195 to $210.
1 week ago benzinga.com
This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
1 week ago benzinga.com
This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated coverage: VSE Sector Weight; Guardant, Quantum, Benitec and Diodes rated Buy/Overweight/Outperform with targets up to $200.
1 week ago 247wallst.com
Here Are Friday’s Top Wall Street Analyst Research Calls: Deckers Outdoor, Globe Life, Guardant Health, Hess Midstream LP, Kimberly-Clark, Natera, NVR, SpaceX, Thermo Fisher Scientific, and More
A wild Thursday saw Treasury yields crater, oil surge past $111, crypto liquidations top $431 million, and Meta's cash flow surprise rattle markets. Now analysts are reshuffling their calls on some…
-
1 week ago benzinga.com
Roth Capital Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $200
Roth Capital analyst Max Masucci initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $200.
1 week ago defenseworld.net
Guardant Health, Inc. (NASDAQ:GH) Stock Has Average Price Target of $190.00
Guardant Health, Inc. (NASDAQ: GH - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twenty-five ratings firms that are currently covering the stock, Marketbeat…
1 week ago businesswire.com
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25…
1 week ago marketbeat.com
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
Rate and energy headlines have kept the broad market jumpy, yet one sector keeps finding buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to…
-
2 weeks ago benzinga.com
TwinStrand Biosciences Announces U.S. Patent And Trademark Office's Patent Trial And Appeal Board Rejects Guardant Health's Challenge To Core Patent Underlying Duplex Sequencing
TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing® technology, today announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has again rejected…
2 weeks ago zacks.com
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
2 weeks ago gurufocus.com
Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing
2 weeks ago businesswire.com
Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing the…
2 weeks ago defenseworld.net
Reviewing The Pennant Group (NASDAQ:PNTG) and Guardant Health (NASDAQ:GH)
Guardant Health (NASDAQ: GH - Get Free Report) and The Pennant Group (NASDAQ: PNTG - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two…
-
2 weeks ago benzinga.com
Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $200
Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $185 to $200.
-
3 weeks ago benzinga.com
Guardant Health Receives European Approval Of Guardant360 CDx As Companion Diagnostic For AstraZeneca’s ETCAMAH
Guardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes in major global geographiesThis latest approval marks Guardant’s 31st CDx approval
3 weeks ago businesswire.com
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360® CDx has received CE-marking under Europe's in Vitro…
3 weeks ago businesswire.com
Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2026 after…
-
3 weeks ago benzinga.com
Barclays Maintains Overweight on Guardant Health, Raises Price Target to $220
Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $200 to $220.
3 weeks ago benzinga.com
S&P 500, Nasdaq Hit Records, Power Stocks Rally on Google's Nuclear Deal: Stock Market Today
S&P 500 and Nasdaq 100 hit records as the 10-year yield retreats from a 24-year high; Constellation Energy jumps on a Google nuclear deal.
3 weeks ago fxempire.com
Guardant Health (GH) Price Forecast: Breakout Opens Path Toward $250
Guardant Health reaches record highs as bullish patterns align across timeframes, opening potential upside toward $250 if buyers defend key breakout support.
-
3 weeks ago benzinga.com
Guardant Health Announces Results From Its COSMOS-MEL01 Trial Shows 81% Sensitivity For Distant Recurrence, 100% Post-Treatment Facility
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published…
3 weeks ago businesswire.com
Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Cancer Research Communications, a journal of the American Association for…
4 weeks ago defenseworld.net
Reviewing Guardant Health (NASDAQ:GH) & Privia Health Group (NASDAQ:PRVA)
Privia Health Group (NASDAQ: PRVA - Get Free Report) and Guardant Health (NASDAQ: GH - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two…
-
1 month ago benzinga.com
Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $200
Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $190 to $200.
1 month ago etftrends.com
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled…
1 month ago defenseworld.net
Reviewing Guardant Health (NASDAQ:GH) & CorVel (NASDAQ:CRVL)
CorVel (NASDAQ: CRVL - Get Free Report) and Guardant Health (NASDAQ: GH - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the…
1 month ago investors.com
AI-Fueled Precision Oncology Firm Guardant Health Is In Focus. Here's Why.
Earning a spot on the IBD Leaderboard and IBD 50, Guardant Health stress tests a breakout.
-
1 month ago benzinga.com
Guardant Health’s Shield Blood Test For Colorectal Cancer Screening To Be Covered In EviCore By Evernorth Clinical Guidelines Effective January 1, 2027, Per ACS Guidelines
Second largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholdersMilestone marks rapid…
-
1 month ago benzinga.com
UBS Maintains Buy on Guardant Health, Raises Price Target to $225
UBS analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $175 to $225.
-
1 month ago benzinga.com
Rothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203
Rothschild & Co analyst Jamie Clark initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $203.
2 months ago benzinga.com
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.
-
2 months ago benzinga.com
Carelon Health Services To Cover Guardant Health’s Shield Blood Test
Largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholdersIncreasing total covered Shield…
2 months ago benzinga.com
Guardant Health Hit With Ongoing Royalties Over Duplex Sequencing Tech
Guardant Health must pay TwinStrand Biosciences and the University of Washington over $245 million after a court finalized a patent dispute.
-
2 months ago benzinga.com
Piper Sandler Maintains Overweight on Guardant Health, Raises Price Target to $193
Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $135 to $193.
-
2 months ago benzinga.com
Stephens & Co. Maintains Overweight on Guardant Health, Raises Price Target to $195
Stephens & Co. analyst Mason Carrico maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $170 to $195.
-
2 months ago benzinga.com
Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $185
Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $175 to $185.
-
3 months ago benzinga.com
Stifel Maintains Buy on Guardant Health, Raises Price Target to $180
Stifel analyst Daniel Arias maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $130 to $180.
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on Guardant Health, Raises Price Target to $200
RBC Capital analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price target from $185 to $200.
-
3 months ago benzinga.com
Mizuho Maintains Outperform on Guardant Health, Raises Price Target to $200
Mizuho analyst Anthony Petrone maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price target from $175 to $200.
-
3 months ago benzinga.com
JP Morgan Maintains Overweight on Guardant Health, Raises Price Target to $195
JP Morgan analyst Casey Woodring maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $185 to $195.
-
3 months ago benzinga.com
TD Cowen Maintains Buy on Guardant Health, Raises Price Target to $210
TD Cowen analyst Dan Brennan maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $200 to $210.
3 months ago benzinga.com
AXT Posts Upbeat Q2 Earnings, Joins Newell Brands, SPX Technologies, Amazon And Other Big Stocks Moving Higher On Friday
U.S. stocks mixed, Nasdaq up 50 pts. AXT Inc (NASDAQ: AXTI) rose 25.3% on strong Q2 results. Other gainers include NWL, FET, IESC, SPXC, AMZN, SPSC, DLB, GH, DXCM, and MPWR.
3 months ago benzinga.com
Amazon To Rally Around 55%? Here Are 10 Top Analyst Forecasts For Friday
Analysts change outlook & price targets for Crocs, Monolithic Power, Axos Financial, Amazon, Karyopharm, Apple, Guardant Health, Pagaya Tech.
-
3 months ago benzinga.com
BTIG Maintains Buy on Guardant Health, Raises Price Target to $195
BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $190 to $195.
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure…
-
3 months ago benzinga.com
Guardant Health Raises FY2026 Sales Guidance from $1.300B-$1.320B to $1.340B-$1.360B vs $1.314B Est
Guardant Health (NASDAQ:GH) raises FY2026 sales outlook from $1.300 billion-$1.320 billion to $1.340 billion-$1.360 billion vs $1.314 billion estimate.
-
3 months ago benzinga.com
Guardant Health Q2 Adj. EPS $(0.42) Misses $(0.41) Estimate, Sales $334.978M Beat $314.226M Estimate
Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.41) by 2.44 percent. This is a 4.55 percent increase over losses of…